文献速递免疫规划传染病防控与疫情报告

BNT162b2与CoronaVac对儿童和青少年COVID-19相关严重结局的有效性:巴西全国队列研究

Effectiveness of BNT162b2 and CoronaVac against COVID-19-related severe outcomes among children and adolescents: A Brazilian nationwide cohort study.
PubMed 文献 · Vaccine · 2024-11-26

该研究基于巴西全国数据库,评估2022年奥密克戎波期间BNT162b2和CoronaVac对5-11岁儿童及12-17岁青少年COVID-19相关严重结局的疫苗有效性(VE)。结果显示,完成两剂接种后,儿童住院、有创通气需求和死亡的VE分别为58%、74%和88%,青少年分别为72%、78%和80%;在完成全程接种的学龄儿童中,CoronaVac对BNT162b2非劣效。

要点

  • 学龄儿童完成两剂接种后,针对SARS住院、有创通气需求和死亡的VE分别为58%、74%和88%。
  • 青少年完成两剂接种后,针对相同结局的VE分别为72%、78%和80%。
  • 在完成全程接种的学龄儿童中,CoronaVac对所有结局均非劣效于BNT162b2。

核心结论

  • COVID-19疫苗对学龄儿童和青少年的严重结局有效,且即使单剂接种也对死亡有保护作用。
  • 在学龄儿童中,CoronaVac不劣于BNT162b2。

研究设计与样本

  • 巴西全国性基于人群的队列研究,比较2022年学龄儿童(5-11岁)和青少年(12-17岁)按接种状态(未接种、一剂或两剂)分层的COVID-19相关严重急性呼吸综合征(SARS)住院、需要有创通气支持和死亡的发病风险比(IRR)。
  • 学龄儿童分析时段为流行病学周(EW)10至34,青少年为EW 1至22。
  • 数据来源于OpenDATASUS中所有因实验室确诊COVID-19相关SARS住院的个体,疫苗覆盖率来自巴西卫生部Vacinômetro COVID-19 dashboard。
  • 纳入分析人群为19,219,424名学龄儿童和22,580,918名青少年。

主要发现

  • 学龄儿童接种一剂和两剂后,针对SARS住院的VE分别为61%和58%,针对有创通气支持的VE分别为62%和74%,针对死亡的VE分别为81%和88%(所有p < 0.01)。
  • 青少年接种一剂和两剂后,针对SARS住院的VE分别为55%和72%,针对有创通气支持的VE分别为60%和78%,针对死亡的VE分别为83%和80%(所有p < 0.05)。
  • 在完成全程接种的学龄儿童中,CoronaVac对所有结局均非劣效于BNT162b2。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Nationwide databases from large countries may provide real-world evidence about COVID-19 vaccine effectiveness (VE). This study sought to assess the VE of BNT162b2 and CoronaVac against COVID-19-related severe outcomes in school-aged children and adolescents during the Omicron wave of the COVID-19 pandemic in Brazil. METHODS: A nationwide population-based cohort study compared the incidence risk ratios (IRRs) of hospitalization due to COVID-19-associated severe acute respiratory syndrome (SARS), need for invasive ventilatory support, and death among school-aged children (age 5 to 11 years) and adolescents (age 12 to 17 years), stratified by vaccination status (none, one, or two doses), in 2022. The period included epidemiological weeks (EW) 10 to 34 for school-aged children and EW 1 to EW 22 for adolescents. Data from all individuals hospitalized due to laboratory-confirmed COVID-19-related SARS were extracted from OpenDATASUS, where individual data including clinical outcomes and vaccination status are available. Vaccine coverage was estimated using data from the Brazilian Ministry of Health "Vacinômetro COVID-19" dashboard. RESULTS: An eligible population of 19,219,424 school-aged children and 22,580,918 adolescents was assessed. For school-aged children, the VE against hospitalization for SARS, invasive ventilatory support, and death after one and two doses was 61 % and 58 %, 62 % and 74 %, and 81 % and 88 %, respectively (all p < 0.01). Among adolescents, the VE against the same outcomes after one and two doses was 55 % and 72 %, 60 % and 78 %, and 83 % and 80 %, respectively (all p < 0.05). CoronaVac was noninferior to BNT162b2 considering all outcomes among fully vaccinated school-aged children, a group that could have received either of the two vaccines. CONCLUSIONS: COVID-19 vaccines are effective against severe outcomes in school-aged children and adolescents and are protective against mortality even after a single dose. CoronaVac was not inferior to BNT162b2 in school-aged children.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. de Lima EDS, Antunes MOB, de Souza JS, et al. Effectiveness of BNT162b2 and CoronaVac against COVID-19-related severe outcomes among children and adolescents: A Brazilian nationwide cohort study. Vaccine. 2024. PMID: 39603074. doi:10.1016/j.vaccine.2024.126550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。